Loading…

Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial

Esophageal cancer often presents as advanced stage disease with a dismal prognosis, with only 10–15% of patients surviving 5 years. Therefore, in a large proportion of patients, palliative treatment is the only option available. The aim of this study was to prospectively compare the palliative effec...

Full description

Saved in:
Bibliographic Details
Published in:Diseases of the esophagus 2005-01, Vol.18 (3), p.131-139
Main Authors: Bergquist, H., Wenger, U., Johnsson, E., Nyman, J., Ejnell, H., Hammerlid, E., Lundell, L., Ruth, M.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4927-30072250c5bad41e3ba53a0a2a6e80486f4247ac553c0bc1e13009265918aa603
cites cdi_FETCH-LOGICAL-c4927-30072250c5bad41e3ba53a0a2a6e80486f4247ac553c0bc1e13009265918aa603
container_end_page 139
container_issue 3
container_start_page 131
container_title Diseases of the esophagus
container_volume 18
creator Bergquist, H.
Wenger, U.
Johnsson, E.
Nyman, J.
Ejnell, H.
Hammerlid, E.
Lundell, L.
Ruth, M.
description Esophageal cancer often presents as advanced stage disease with a dismal prognosis, with only 10–15% of patients surviving 5 years. Therefore, in a large proportion of patients, palliative treatment is the only option available. The aim of this study was to prospectively compare the palliative effect of self‐expandable stent placement with that of endoluminal brachytherapy regarding the effect on quality of life and on specific symptoms. Sixty‐five patients with advanced cancer of the esophagus or gastroesophageal junction were randomized to treatment with either an Ultraflex expandable stent or high‐dose‐rate endoluminal brachytherapy with 7 Gy × 3 given in 2–4 weeks. Clinical assessment and health‐related quality of life (HRQL) were measured at inclusion and 1, 3, 6, 9 and 12 months later. The HRQL was measured with standardized questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Oesophageal Module and Hospital Anxiety and Depression Scale). Twenty‐eight patients completed the stent treatment and 24 patients the brachytherapy. The group of patients treated with stent reported significantly better HRQL scores for dysphagia (P 
doi_str_mv 10.1111/j.1442-2050.2005.00467.x
format article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_gup_ub_gu_se_47251</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68079714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4927-30072250c5bad41e3ba53a0a2a6e80486f4247ac553c0bc1e13009265918aa603</originalsourceid><addsrcrecordid>eNqNkc1u1DAURiMEoqXwCsgrVk2wHTtOFixQW1qkikqlwNK6cTwzHjx2aifMDA_XZ8Mho2GLN9c_53xefFmGCC5IWu_XBWGM5hRzXFCMeYExq0Sxe5adHh-epz2hOK-rhp1kr2JcY0xEWdUvsxNSYca5oKfZ09dBuwEZF3UYjHfIB6Rd5-24MQ4sagOo1X5Y6QD9HkFEPVhrYEYX6TSY5Ee0NcMKQfcLnNIdUtMIE5BMpKPvV7AcIwLXoSXEIfjDnU5frEenprwC3es42hSWPEAhwX5jfuvuHCnvkmPtFG2NMyppQzBgX2cvFmCjfnOYZ9m3T1cPFzf57d3154uPt7liDRV5ibGglGPFW-gY0WULvAQMFCpdY1ZXC0aZAMV5qXCriCbJaGjFG1IDVLg8y87n3LjV_djKPpgNhL30YORy7GW6Wo4yaskE5STh72a8D_5x1HGQGxOVthac9mOUVY1FIwhLYD2DKvgYg14ckwmWU9VyLadG5dSonKqWf6uWu6S-Pfwxthvd_RMP3SbgwwxsjdX7_w6Wl3cPV2mX_Hz2TRz07uhD-CnTq-Dyx5dr-Z1c8nsmGlmVfwAHtsuY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68079714</pqid></control><display><type>article</type><title>Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial</title><source>Oxford Journals Online</source><creator>Bergquist, H. ; Wenger, U. ; Johnsson, E. ; Nyman, J. ; Ejnell, H. ; Hammerlid, E. ; Lundell, L. ; Ruth, M.</creator><creatorcontrib>Bergquist, H. ; Wenger, U. ; Johnsson, E. ; Nyman, J. ; Ejnell, H. ; Hammerlid, E. ; Lundell, L. ; Ruth, M.</creatorcontrib><description>Esophageal cancer often presents as advanced stage disease with a dismal prognosis, with only 10–15% of patients surviving 5 years. Therefore, in a large proportion of patients, palliative treatment is the only option available. The aim of this study was to prospectively compare the palliative effect of self‐expandable stent placement with that of endoluminal brachytherapy regarding the effect on quality of life and on specific symptoms. Sixty‐five patients with advanced cancer of the esophagus or gastroesophageal junction were randomized to treatment with either an Ultraflex expandable stent or high‐dose‐rate endoluminal brachytherapy with 7 Gy × 3 given in 2–4 weeks. Clinical assessment and health‐related quality of life (HRQL) were measured at inclusion and 1, 3, 6, 9 and 12 months later. The HRQL was measured with standardized questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Oesophageal Module and Hospital Anxiety and Depression Scale). Twenty‐eight patients completed the stent treatment and 24 patients the brachytherapy. The group of patients treated with stent reported significantly better HRQL scores for dysphagia (P &lt; 0.05) at the 1‐month follow‐up, but most other HRQL scores, including functioning and symptom scales, deteriorated. Among brachytherapy‐treated patients, improvement was found for the dysphagia‐related scores at the 3‐months follow‐up, whereas other significant changes of scores were few. The median survival time was comparable in the two groups (around 120 days). In conclusion, insertion of self‐expandable metal stents offered a more instant relief of dysphagia compared to endoluminal brachytherapy, but HRQL was more stable in the brachytherapy group.</description><identifier>ISSN: 1120-8694</identifier><identifier>EISSN: 1442-2050</identifier><identifier>DOI: 10.1111/j.1442-2050.2005.00467.x</identifier><identifier>PMID: 16045572</identifier><language>eng</language><publisher>550 Swanston Street (PO Box 378) Carlton South, Victoria 3053 Australia: Blackwell Science Pty</publisher><subject>Aged ; Aged, 80 and over ; Brachytherapy ; Brachytherapy - methods ; Deglutition Disorders - etiology ; Deglutition Disorders - therapy ; esophageal neoplasms ; Esophageal Neoplasms - complications ; Esophageal Neoplasms - pathology ; Esophageal Neoplasms - therapy ; Esophagogastric Junction ; Female ; Humans ; Male ; Neoplasm Staging ; Oto-rino-laryngologi ; Otorhinolaryngology ; palliative care ; Palliative Care - methods ; Prospective Studies ; Prosthesis Implantation - instrumentation ; Quality of Life ; Stents</subject><ispartof>Diseases of the esophagus, 2005-01, Vol.18 (3), p.131-139</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4927-30072250c5bad41e3ba53a0a2a6e80486f4247ac553c0bc1e13009265918aa603</citedby><cites>FETCH-LOGICAL-c4927-30072250c5bad41e3ba53a0a2a6e80486f4247ac553c0bc1e13009265918aa603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16045572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/47251$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Bergquist, H.</creatorcontrib><creatorcontrib>Wenger, U.</creatorcontrib><creatorcontrib>Johnsson, E.</creatorcontrib><creatorcontrib>Nyman, J.</creatorcontrib><creatorcontrib>Ejnell, H.</creatorcontrib><creatorcontrib>Hammerlid, E.</creatorcontrib><creatorcontrib>Lundell, L.</creatorcontrib><creatorcontrib>Ruth, M.</creatorcontrib><title>Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial</title><title>Diseases of the esophagus</title><addtitle>Dis Esophagus</addtitle><description>Esophageal cancer often presents as advanced stage disease with a dismal prognosis, with only 10–15% of patients surviving 5 years. Therefore, in a large proportion of patients, palliative treatment is the only option available. The aim of this study was to prospectively compare the palliative effect of self‐expandable stent placement with that of endoluminal brachytherapy regarding the effect on quality of life and on specific symptoms. Sixty‐five patients with advanced cancer of the esophagus or gastroesophageal junction were randomized to treatment with either an Ultraflex expandable stent or high‐dose‐rate endoluminal brachytherapy with 7 Gy × 3 given in 2–4 weeks. Clinical assessment and health‐related quality of life (HRQL) were measured at inclusion and 1, 3, 6, 9 and 12 months later. The HRQL was measured with standardized questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Oesophageal Module and Hospital Anxiety and Depression Scale). Twenty‐eight patients completed the stent treatment and 24 patients the brachytherapy. The group of patients treated with stent reported significantly better HRQL scores for dysphagia (P &lt; 0.05) at the 1‐month follow‐up, but most other HRQL scores, including functioning and symptom scales, deteriorated. Among brachytherapy‐treated patients, improvement was found for the dysphagia‐related scores at the 3‐months follow‐up, whereas other significant changes of scores were few. The median survival time was comparable in the two groups (around 120 days). In conclusion, insertion of self‐expandable metal stents offered a more instant relief of dysphagia compared to endoluminal brachytherapy, but HRQL was more stable in the brachytherapy group.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Brachytherapy</subject><subject>Brachytherapy - methods</subject><subject>Deglutition Disorders - etiology</subject><subject>Deglutition Disorders - therapy</subject><subject>esophageal neoplasms</subject><subject>Esophageal Neoplasms - complications</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Neoplasms - therapy</subject><subject>Esophagogastric Junction</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasm Staging</subject><subject>Oto-rino-laryngologi</subject><subject>Otorhinolaryngology</subject><subject>palliative care</subject><subject>Palliative Care - methods</subject><subject>Prospective Studies</subject><subject>Prosthesis Implantation - instrumentation</subject><subject>Quality of Life</subject><subject>Stents</subject><issn>1120-8694</issn><issn>1442-2050</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqNkc1u1DAURiMEoqXwCsgrVk2wHTtOFixQW1qkikqlwNK6cTwzHjx2aifMDA_XZ8Mho2GLN9c_53xefFmGCC5IWu_XBWGM5hRzXFCMeYExq0Sxe5adHh-epz2hOK-rhp1kr2JcY0xEWdUvsxNSYca5oKfZ09dBuwEZF3UYjHfIB6Rd5-24MQ4sagOo1X5Y6QD9HkFEPVhrYEYX6TSY5Ee0NcMKQfcLnNIdUtMIE5BMpKPvV7AcIwLXoSXEIfjDnU5frEenprwC3es42hSWPEAhwX5jfuvuHCnvkmPtFG2NMyppQzBgX2cvFmCjfnOYZ9m3T1cPFzf57d3154uPt7liDRV5ibGglGPFW-gY0WULvAQMFCpdY1ZXC0aZAMV5qXCriCbJaGjFG1IDVLg8y87n3LjV_djKPpgNhL30YORy7GW6Wo4yaskE5STh72a8D_5x1HGQGxOVthac9mOUVY1FIwhLYD2DKvgYg14ckwmWU9VyLadG5dSonKqWf6uWu6S-Pfwxthvd_RMP3SbgwwxsjdX7_w6Wl3cPV2mX_Hz2TRz07uhD-CnTq-Dyx5dr-Z1c8nsmGlmVfwAHtsuY</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>Bergquist, H.</creator><creator>Wenger, U.</creator><creator>Johnsson, E.</creator><creator>Nyman, J.</creator><creator>Ejnell, H.</creator><creator>Hammerlid, E.</creator><creator>Lundell, L.</creator><creator>Ruth, M.</creator><general>Blackwell Science Pty</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>F1U</scope></search><sort><creationdate>20050101</creationdate><title>Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial</title><author>Bergquist, H. ; Wenger, U. ; Johnsson, E. ; Nyman, J. ; Ejnell, H. ; Hammerlid, E. ; Lundell, L. ; Ruth, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4927-30072250c5bad41e3ba53a0a2a6e80486f4247ac553c0bc1e13009265918aa603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Brachytherapy</topic><topic>Brachytherapy - methods</topic><topic>Deglutition Disorders - etiology</topic><topic>Deglutition Disorders - therapy</topic><topic>esophageal neoplasms</topic><topic>Esophageal Neoplasms - complications</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Neoplasms - therapy</topic><topic>Esophagogastric Junction</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasm Staging</topic><topic>Oto-rino-laryngologi</topic><topic>Otorhinolaryngology</topic><topic>palliative care</topic><topic>Palliative Care - methods</topic><topic>Prospective Studies</topic><topic>Prosthesis Implantation - instrumentation</topic><topic>Quality of Life</topic><topic>Stents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bergquist, H.</creatorcontrib><creatorcontrib>Wenger, U.</creatorcontrib><creatorcontrib>Johnsson, E.</creatorcontrib><creatorcontrib>Nyman, J.</creatorcontrib><creatorcontrib>Ejnell, H.</creatorcontrib><creatorcontrib>Hammerlid, E.</creatorcontrib><creatorcontrib>Lundell, L.</creatorcontrib><creatorcontrib>Ruth, M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Göteborgs universitet</collection><jtitle>Diseases of the esophagus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bergquist, H.</au><au>Wenger, U.</au><au>Johnsson, E.</au><au>Nyman, J.</au><au>Ejnell, H.</au><au>Hammerlid, E.</au><au>Lundell, L.</au><au>Ruth, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial</atitle><jtitle>Diseases of the esophagus</jtitle><addtitle>Dis Esophagus</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>18</volume><issue>3</issue><spage>131</spage><epage>139</epage><pages>131-139</pages><issn>1120-8694</issn><eissn>1442-2050</eissn><abstract>Esophageal cancer often presents as advanced stage disease with a dismal prognosis, with only 10–15% of patients surviving 5 years. Therefore, in a large proportion of patients, palliative treatment is the only option available. The aim of this study was to prospectively compare the palliative effect of self‐expandable stent placement with that of endoluminal brachytherapy regarding the effect on quality of life and on specific symptoms. Sixty‐five patients with advanced cancer of the esophagus or gastroesophageal junction were randomized to treatment with either an Ultraflex expandable stent or high‐dose‐rate endoluminal brachytherapy with 7 Gy × 3 given in 2–4 weeks. Clinical assessment and health‐related quality of life (HRQL) were measured at inclusion and 1, 3, 6, 9 and 12 months later. The HRQL was measured with standardized questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Oesophageal Module and Hospital Anxiety and Depression Scale). Twenty‐eight patients completed the stent treatment and 24 patients the brachytherapy. The group of patients treated with stent reported significantly better HRQL scores for dysphagia (P &lt; 0.05) at the 1‐month follow‐up, but most other HRQL scores, including functioning and symptom scales, deteriorated. Among brachytherapy‐treated patients, improvement was found for the dysphagia‐related scores at the 3‐months follow‐up, whereas other significant changes of scores were few. The median survival time was comparable in the two groups (around 120 days). In conclusion, insertion of self‐expandable metal stents offered a more instant relief of dysphagia compared to endoluminal brachytherapy, but HRQL was more stable in the brachytherapy group.</abstract><cop>550 Swanston Street (PO Box 378) Carlton South, Victoria 3053 Australia</cop><pub>Blackwell Science Pty</pub><pmid>16045572</pmid><doi>10.1111/j.1442-2050.2005.00467.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1120-8694
ispartof Diseases of the esophagus, 2005-01, Vol.18 (3), p.131-139
issn 1120-8694
1442-2050
language eng
recordid cdi_swepub_primary_oai_gup_ub_gu_se_47251
source Oxford Journals Online
subjects Aged
Aged, 80 and over
Brachytherapy
Brachytherapy - methods
Deglutition Disorders - etiology
Deglutition Disorders - therapy
esophageal neoplasms
Esophageal Neoplasms - complications
Esophageal Neoplasms - pathology
Esophageal Neoplasms - therapy
Esophagogastric Junction
Female
Humans
Male
Neoplasm Staging
Oto-rino-laryngologi
Otorhinolaryngology
palliative care
Palliative Care - methods
Prospective Studies
Prosthesis Implantation - instrumentation
Quality of Life
Stents
title Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A15%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stent%20insertion%20or%20endoluminal%20brachytherapy%20as%20palliation%20of%20patients%20with%20advanced%20cancer%20of%20the%20esophagus%20and%20gastroesophageal%20junction.%20Results%20of%20a%20randomized,%20controlled%20clinical%20trial&rft.jtitle=Diseases%20of%20the%20esophagus&rft.au=Bergquist,%20H.&rft.date=2005-01-01&rft.volume=18&rft.issue=3&rft.spage=131&rft.epage=139&rft.pages=131-139&rft.issn=1120-8694&rft.eissn=1442-2050&rft_id=info:doi/10.1111/j.1442-2050.2005.00467.x&rft_dat=%3Cproquest_swepu%3E68079714%3C/proquest_swepu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4927-30072250c5bad41e3ba53a0a2a6e80486f4247ac553c0bc1e13009265918aa603%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68079714&rft_id=info:pmid/16045572&rfr_iscdi=true